Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
May inform mechanism-based therapies in sarcomeric cardiomyopathies; leaves open clinical validation in prospective trials.
The sarcomere is the principal contractile unit of striated muscle. Mutations in genes encoding sarcomeric proteins are responsible for a range of diseases including hypertrophic, dilated and restrictive cardiomyopathies and ventricular non-compaction. The downstream molecular pathways leading to these heterogeneous phenotypes include changes in acto-myosin cross-bridge kinetics, altered mechanosensation, disturbed calcium sensitivity, de-regulated signalling pathways, inefficient energetics, myocardial ischaemia and fibrosis. The elucidation of the genetic causes of cardiomyopathy has helped in understanding the structure and function of the sarcomere and a more detailed knowledge of the sarcomere and its associated proteins has suggested additional gene candidates. The new hope is that these advances will stimulate the discovery of disease-modifying drugs.
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: